Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART

This study has been completed.
Sponsor:
Collaborators:
Triangle Pharmaceuticals
Gilead Sciences
Bristol-Myers Squibb
Dupont Applied Biosciences
Information provided by:
French National Agency for Research on AIDS and Viral Hepatitis
ClinicalTrials.gov Identifier:
NCT00196612
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted